Bio-Rad Laboratories, Inc. — 2020 Form 10-K
Business context and period: Annual report for the fiscal year ended December 31, 2020. Bio-Rad sells life science research and clinical diagnostics products worldwide. Life Science and Clinical Diagnostics represented 49% and 51% of annual net sales, respectively; approximately 61% of sales were international.
Financial performance
| Metric | 2020 | 2019 | Change / context |
|---|---|---|---|
| Net sales | $2.546 billion | $2.312 billion | Up 10.1% (10.3% currency-neutral) |
| Gross profit / margin | $1.438 billion / 56.5% | $1.257 billion / 54.4% | Margin increased 2.1 percentage points |
| Operating income | $411.0 million | $229.7 million | Operating margin about 16.1%, versus 9.9% |
| Net income / diluted EPS | $3.806 billion / $126.20 | $1.759 billion / $58.27 | Results were dominated by unrealized Sartorius investment gains |
| Operating cash flow | $575.3 million | $457.9 million | Up $117.4 million |
| Cash, cash equivalents and short-term investments | $991.1 million | $1.115 billion | About 37% of 2020 cash and short-term investments held by foreign subsidiaries |
| Total assets / stockholders’ equity | $12.973 billion / $9.880 billion | $8.009 billion / $5.755 billion | Increase primarily reflects investment appreciation |
| Debt | $14.1 million | $439.8 million | $425 million senior notes repaid in December 2020 |
Quarterly context: Unaudited fourth-quarter 2020 net sales were $789.8 million, compared with $624.5 million in Q4 2019. Q4 net income was $839.2 million versus $553.5 million. Quarterly net income also reflects material equity-security valuation gains; the filing text does not provide a clear Q4-only amount for those gains.
Segments and material year-over-year changes
- Life Science: Sales were $1.232 billion, up 39.0% (38.6% currency-neutral). Growth was led by Gene Expression, Droplet Digital PCR and Process Media, with COVID-19-related products also contributing. Segment profit rose to $256.3 million from $72.1 million.
- Clinical Diagnostics: Sales were $1.305 billion, down 7.6% (7.1% currency-neutral), with declines across regions and most product lines. COVID-19-related disruption to customer operations and routine testing weighed on demand. Segment profit was $149.1 million, compared with $148.5 million.
- Consolidated SG&A declined to $800.3 million from $824.6 million, partly due to $35 million lower travel, marketing and communications costs, largely related to the pandemic. R&D increased to $226.6 million from $202.7 million.
- The $4.496 billion gain in fair value of equity securities, primarily Bio-Rad’s Sartorius AG holding, substantially drove reported net income. The corresponding gain in 2019 was $2.031 billion. These gains are not a measure of operating performance and can reverse with market prices.
Cash, liquidity and other notable items
- Operating cash flow rose to $575.3 million, mainly reflecting higher customer receipts associated with COVID-19 product sales. Net income is not a useful proxy for cash generation in this period: the cash-flow reconciliation removed $4.496 billion of equity-security gains, and deferred income tax expense was $978.9 million.
- Current assets were $2.140 billion and current liabilities $631.5 million at year-end. The company reported $991.1 million in cash, cash equivalents and short-term investments and no borrowings under its $200 million revolving credit facility; $0.2 million was used for standby letters of credit. Management said available liquidity and operating cash flow were adequate for current objectives.
- Bio-Rad repurchased $100 million of shares in 2020 and had $273.1 million remaining under its authorization at year-end. It has never paid a cash dividend and reported no present plan to do so.
- The company acquired Celsee for total consideration of $99.3 million, including contingent consideration, and sold its Informatics division for $12.2 million, recognizing an $11.7 million gain.
- In Q4, Bio-Rad received $35.3 million in court-awarded intellectual-property damages and recognized $32.3 million as revenue. The award related to infringing product sales from 2015–2018.
Outlook, risks and contingencies
- Management gave no quantified 2021 revenue or earnings guidance in the provided filing text. It cautioned that the pandemic’s duration and effects are uncertain: demand for COVID-19-related products was strong, while other businesses faced reduced customer activity. Supplier, component and freight constraints were also reported.
- A February 2021 restructuring, a subsequent event, is expected to eliminate about 530 positions and create about 325 positions, primarily in Europe, including moving some manufacturing to Asia. Estimated total costs are $125–$130 million, including about $86 million in cash employee costs, $19 million in capital expenditures and $20–$25 million in transition costs. The company expected $80–$90 million of charges in Q1 2021 and substantial completion by the end of 2022; estimates may change.
- Investment concentration is significant: the Sartorius holding had a reported fair value of approximately $9.582 billion at year-end, versus $4.664 billion in 2019. Bio-Rad warned that valuation swings can materially affect earnings and share price and could create a risk of being deemed an investment company, potentially limiting capital-market access.
- Other key risks include COVID-19 and supply-chain disruption, foreign-exchange exposure, competition and pricing pressure, regulatory and reimbursement changes, product quality and liability, cybersecurity and ERP implementation. The December 2019 cyberattack caused disruption; the company reported no evidence of personal-data misuse, no customer-system impact and no ransom payment.
- Ordinary-course legal matters remain pending; the company said it cannot reasonably estimate potential exposure. It did not believe those matters would ultimately materially affect results, financial position or liquidity, but gave no assurance on outcomes.
Important facts for investors to verify
- Separate core operating trends from Sartorius fair-value gains when assessing earnings, EPS and valuation; monitor the investment’s size, market value, tax effects and any investment-company status implications.
- Track whether Life Science growth persists as pandemic-related demand changes, and whether Clinical Diagnostics recovers from lower routine testing and customer activity.
- Compare cash flow and working-capital trends with reported earnings, including the large noncash equity gain and deferred tax expense.
- Monitor restructuring execution, actual cash costs, timing of charges and savings, and any effects on European operations, supply continuity or customer service.
- Review subsequent disclosures for COVID-19 demand and supply conditions, the Celsee earn-out, tax examinations and legal contingencies. The financial statements and internal control over financial reporting received unqualified audit opinions.